Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Technologies Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
•  LIQ861 was well-tolerated in PAH patients at two months of treatment •  INSPIRE enrollment complete, including PK sub-study •  Anticipate submitting NDA for LIQ861 to the FDA in late 2019 RESEARCH TRIANGLE PARK, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trial Accepted by FDA into Emerging Technology Program to support review of PRINT ® technology Management to host webcast and conference call today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Feb.
View HTML
Toggle Summary Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019
RESEARCH TRIANGLE PARK, N.C. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDA NDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical
View HTML
Toggle Summary Liquidia Technologies Provides Leadership Update
RESEARCH TRIANGLE PARK, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
RESEARCH TRIANGLE PARK, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies to Present at Jefferies London Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trial Two-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019 Dr. Stephen Bloch appointed as Chairman of the Board Management to host webcast and conference call today at 8 a.m.
View HTML